A large-scale international study, led by researchers from the Gray Faculty of Medical and Health Sciences at Tel Aviv University, found a mechanism that allows breast cancer to send metastases to the brain. The findings could enable the development of new drugs and personalized monitoring for early detection and treatment of brain metastases.
Further positive results from the phase III SERENA-6 trial showed camizestrant plus a cyclin-dependent kinase 4/6 inhibitor—palbociclib, ribociclib or abemaciclib—maintained its progression-free survival benefit with longer follow-up and delivered a statistically significant and clinically meaningful improvement in second progression-free survival, demonstrating sustained benefit beyond initial treatment.
